Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety.

Eleni Armeni, Antonio Cano, Margaret Rees, Irene Lambrinoudaki

Abstract readEditorialComment

In one paragraph

Article in Maturitas, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis.International journal of molecular sciences · 2022
Article
Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic.Frontiers in immunology · 2022
Review

4 · The record

Corrections and comments

Comment on
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.2020

5 · Who and what money

Authors and funding

4 authors.

Eleni ArmeniSecond Department of Obstetrics and Gynecology, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, Greece. Electronic address: elenaarmeni@hotmail.com.

Antonio CanoDepartment of Pediatrics, Obstetrics and Gynecology, University of Valencia and INCLIVA, Valencia, Spain.

Margaret ReesWomen's Centre, John Radcliffe Hospital, Oxford, OX3 9DU, UK.

Irene LambrinoudakiSecond Department of Obstetrics and Gynecology, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsFemaleFollow-Up StudiesHormone Replacement TherapyHumansIncidenceMenopauseRandomized Controlled Trials as TopicWomen's Health

Identifiers

PMID32861483

DOI10.1016/j.maturitas.2020.08.001

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.